Patrick Brown
About Patrick Brown
Patrick Brown is a Senior Clinical Trial Physician at Bristol Myers Squibb, with extensive experience in oncology and pediatrics from his tenure at Johns Hopkins Medicine.
Title
Patrick Brown serves as a Senior Clinical Trial Physician at Bristol Myers Squibb in Princeton, New Jersey, United States. His role includes overseeing clinical development activities related to novel targeted agents in hematologic malignancies.
Company
Patrick Brown is currently employed at Bristol Myers Squibb. He is based in Princeton, New Jersey, United States, where the focus is on clinical research and development assessing novel targeted agents in the realm of hematologic malignancies.
Education and Expertise
Patrick Brown has a diverse academic background. He holds a Doctor of Medicine (MD) degree from the Medical University of South Carolina, obtained between 1994 and 1998. Prior to that, he studied Philosophy and Politics at the University of Oxford, earning a Master of Arts (MA) from 1989 to 1991. He began his formal education at the United States Military Academy at West Point, where he achieved a Bachelor of Science (BS) in Engineering, being enrolled from 1985 to 1989. His expertise lies in developing molecularly targeted therapies and immunotherapies for leukemia.
Background
Prior to his current role, Patrick Brown accumulated extensive experience in academic medicine. He worked at Johns Hopkins Medicine in Baltimore, Maryland, for 24 years (1998-2022) as a Professor of Oncology and Pediatrics. His early career included serving as a commissioned officer in the US Army from 1991 to 1994. In May 2022, he transitioned from academic medicine to the pharmaceutical industry, continuing his focus on clinical research and innovative therapies.
Clinical and Research Experience
Throughout his career, Patrick Brown has been deeply involved in both patient care and translational laboratory research. He has significant experience in clinical research and teaching, with a particular emphasis on pediatric oncology. At Bristol Myers Squibb, he focuses on the clinical development of novel targeted agents for hematologic malignancies, utilizing his extensive background in both academic and clinical environments.